JP2022509206A - Ｍａｇｌ阻害剤による疾病の治療方法 - Google Patents
Ｍａｇｌ阻害剤による疾病の治療方法 Download PDFInfo
- Publication number
- JP2022509206A JP2022509206A JP2021529827A JP2021529827A JP2022509206A JP 2022509206 A JP2022509206 A JP 2022509206A JP 2021529827 A JP2021529827 A JP 2021529827A JP 2021529827 A JP2021529827 A JP 2021529827A JP 2022509206 A JP2022509206 A JP 2022509206A
- Authority
- JP
- Japan
- Prior art keywords
- disease
- condition
- compound
- formula
- certain embodiments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)C=CCC(*)=C[C@](C)(*)N=*C Chemical compound CC(C)C=CCC(*)=C[C@](C)(*)N=*C 0.000 description 67
- KAUMXIFOBGXMIF-UHFFFAOYSA-N CN(C1)CC2C1COC2 Chemical compound CN(C1)CC2C1COC2 KAUMXIFOBGXMIF-UHFFFAOYSA-N 0.000 description 3
- SNEQGKPWXUJUIG-UHFFFAOYSA-N CN(CC1)CCN1C1CC1 Chemical compound CN(CC1)CCN1C1CC1 SNEQGKPWXUJUIG-UHFFFAOYSA-N 0.000 description 2
- MCBFNYVOJAYSCR-UHFFFAOYSA-N CN1C2COCC1CC2 Chemical compound CN1C2COCC1CC2 MCBFNYVOJAYSCR-UHFFFAOYSA-N 0.000 description 2
- LNJMHEJAYSYZKK-UHFFFAOYSA-N Cc1ncccn1 Chemical compound Cc1ncccn1 LNJMHEJAYSYZKK-UHFFFAOYSA-N 0.000 description 2
- ZEKBKTMMBLWNGK-UHFFFAOYSA-N CC(C)(C)c1nnn[nH]1 Chemical compound CC(C)(C)c1nnn[nH]1 ZEKBKTMMBLWNGK-UHFFFAOYSA-N 0.000 description 1
- AWYOANDNNWXEQT-LNSVPDHHSA-N CC(C)COC(C1C2[IH]C2)C=CC=C1O[C@@H](C1)C[C@@H](C2)[C@H]1CN2C(N(CC1)N=C1C(O)=O)=O Chemical compound CC(C)COC(C1C2[IH]C2)C=CC=C1O[C@@H](C1)C[C@@H](C2)[C@H]1CN2C(N(CC1)N=C1C(O)=O)=O AWYOANDNNWXEQT-LNSVPDHHSA-N 0.000 description 1
- HXAWMZDJHKRLOX-UHFFFAOYSA-N CC(C)N(CC1)CCC1OC Chemical compound CC(C)N(CC1)CCC1OC HXAWMZDJHKRLOX-UHFFFAOYSA-N 0.000 description 1
- OQFWCGBXTIYRKF-UHFFFAOYSA-N CC(C)N1CC(CC2)OC2C1 Chemical compound CC(C)N1CC(CC2)OC2C1 OQFWCGBXTIYRKF-UHFFFAOYSA-N 0.000 description 1
- ZQXGZHHTOWJJLB-JTQLQIEISA-N CC(C)N1C[C@H](CCC2)N2CC1 Chemical compound CC(C)N1C[C@H](CCC2)N2CC1 ZQXGZHHTOWJJLB-JTQLQIEISA-N 0.000 description 1
- IYKCETRGBFKTRU-UHFFFAOYSA-N CC(C)c1nnc[o]1 Chemical compound CC(C)c1nnc[o]1 IYKCETRGBFKTRU-UHFFFAOYSA-N 0.000 description 1
- RFFXUEDBNNOGDO-UHFFFAOYSA-N CC(C)c1nnn[nH]1 Chemical compound CC(C)c1nnn[nH]1 RFFXUEDBNNOGDO-UHFFFAOYSA-N 0.000 description 1
- KHSBHAPEBURECN-COYMHYPVSA-N CC(C1)C(C(O)=O)=NN1C(N1[C@@H](C)CN(Cc2cccc(Oc(cc3)ccc3Cl)c2)CC1)O Chemical compound CC(C1)C(C(O)=O)=NN1C(N1[C@@H](C)CN(Cc2cccc(Oc(cc3)ccc3Cl)c2)CC1)O KHSBHAPEBURECN-COYMHYPVSA-N 0.000 description 1
- JFGXGAPLZJVGNF-IGSZECBISA-N CC(CC(C1)C(C2)[O]2c(cccc2OC)c2Cl)(C2)[C@H]1CN2C([n](cc1)nc1C(O)=O)=O Chemical compound CC(CC(C1)C(C2)[O]2c(cccc2OC)c2Cl)(C2)[C@H]1CN2C([n](cc1)nc1C(O)=O)=O JFGXGAPLZJVGNF-IGSZECBISA-N 0.000 description 1
- UYGVTUDOXLXEGH-GQCTYLIASA-N CC/C(/C)=N/N=N\N Chemical compound CC/C(/C)=N/N=N\N UYGVTUDOXLXEGH-GQCTYLIASA-N 0.000 description 1
- NNWUEBIEOFQMSS-UHFFFAOYSA-N CC1NCCCC1 Chemical compound CC1NCCCC1 NNWUEBIEOFQMSS-UHFFFAOYSA-N 0.000 description 1
- SNALRIFMJPORKB-VIFPVBQESA-N CCN1C[C@H](CCC2)N2CC1 Chemical compound CCN1C[C@H](CCC2)N2CC1 SNALRIFMJPORKB-VIFPVBQESA-N 0.000 description 1
- DHNLWBALDJWTTH-UHFFFAOYSA-N CCc1nnc[o]1 Chemical compound CCc1nnc[o]1 DHNLWBALDJWTTH-UHFFFAOYSA-N 0.000 description 1
- LFHMKODCPPOLIB-UHFFFAOYSA-N CN(CC1)CCC1(F)F Chemical compound CN(CC1)CCC1(F)F LFHMKODCPPOLIB-UHFFFAOYSA-N 0.000 description 1
- YNJUHLCZQTYQIS-UHFFFAOYSA-N CN(CC1)CCC1(F)[F]C Chemical compound CN(CC1)CCC1(F)[F]C YNJUHLCZQTYQIS-UHFFFAOYSA-N 0.000 description 1
- JZTHADLNXYYKRA-UHFFFAOYSA-N CN(CC1)CCC1F Chemical compound CN(CC1)CCC1F JZTHADLNXYYKRA-UHFFFAOYSA-N 0.000 description 1
- KHMVSJKIXGNZTN-UHFFFAOYSA-N CN(CC1)CCC1S(C)(=O)=O Chemical compound CN(CC1)CCC1S(C)(=O)=O KHMVSJKIXGNZTN-UHFFFAOYSA-N 0.000 description 1
- HJUXLQPJJHRLCR-UHFFFAOYSA-N CN1C2=CCC1COC2 Chemical compound CN1C2=CCC1COC2 HJUXLQPJJHRLCR-UHFFFAOYSA-N 0.000 description 1
- XJZDIZQNHVHDKM-UHFFFAOYSA-N CN1CC(CC2)OC2C1 Chemical compound CN1CC(CC2)OC2C1 XJZDIZQNHVHDKM-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- XJRPIZCHFSKXPJ-UHFFFAOYSA-N CNCCNC1CC1 Chemical compound CNCCNC1CC1 XJRPIZCHFSKXPJ-UHFFFAOYSA-N 0.000 description 1
- PYKOUNQHZVLMLL-NVHKAFQKSA-N C[C@@H](CN(Cc1cccc(Oc(cc2)ccc2Cl)c1)CC1)N1C(N(CC1C(F)(F)F)N=C1C(O)=O)=C1CC1 Chemical compound C[C@@H](CN(Cc1cccc(Oc(cc2)ccc2Cl)c1)CC1)N1C(N(CC1C(F)(F)F)N=C1C(O)=O)=C1CC1 PYKOUNQHZVLMLL-NVHKAFQKSA-N 0.000 description 1
- DLTHEPWEENQLKV-UHFFFAOYSA-N Cc1cnc2[n]1cccc2 Chemical compound Cc1cnc2[n]1cccc2 DLTHEPWEENQLKV-UHFFFAOYSA-N 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N Cc1ncc[s]1 Chemical compound Cc1ncc[s]1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- CDDGNGVFPQRJJM-UHFFFAOYSA-N FC1CNCC1 Chemical compound FC1CNCC1 CDDGNGVFPQRJJM-UHFFFAOYSA-N 0.000 description 1
- VLBBFZPUQGSFOX-UHFFFAOYSA-N O=Cc(cc1)n[n]1C(N(CC1)CCC11N(Cc2ccc(C(F)(F)F)cc2N2CCCC2)CCC1)=O Chemical compound O=Cc(cc1)n[n]1C(N(CC1)CCC11N(Cc2ccc(C(F)(F)F)cc2N2CCCC2)CCC1)=O VLBBFZPUQGSFOX-UHFFFAOYSA-N 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N OC1CCNCC1 Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862772554P | 2018-11-28 | 2018-11-28 | |
| US62/772,554 | 2018-11-28 | ||
| PCT/US2019/063451 WO2020112905A1 (en) | 2018-11-28 | 2019-11-26 | Methods of treating disease with magl inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022509206A true JP2022509206A (ja) | 2022-01-20 |
| JP2022509206A5 JP2022509206A5 (https=) | 2022-11-28 |
| JPWO2020112905A5 JPWO2020112905A5 (https=) | 2022-11-28 |
Family
ID=70851863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529827A Pending JP2022509206A (ja) | 2018-11-28 | 2019-11-26 | Ｍａｇｌ阻害剤による疾病の治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220031676A1 (https=) |
| EP (1) | EP3886844A4 (https=) |
| JP (1) | JP2022509206A (https=) |
| KR (1) | KR20210097734A (https=) |
| CN (1) | CN113347971A (https=) |
| AU (1) | AU2019389017B2 (https=) |
| BR (1) | BR112020015043A2 (https=) |
| CA (1) | CA3120577A1 (https=) |
| CL (1) | CL2021001363A1 (https=) |
| IL (1) | IL283508A (https=) |
| MA (1) | MA54313A (https=) |
| MX (1) | MX2021006312A (https=) |
| SG (1) | SG11202105320YA (https=) |
| WO (1) | WO2020112905A1 (https=) |
| ZA (1) | ZA202103975B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3630744T3 (da) | 2017-05-23 | 2023-03-06 | H Lundbeck As | Pyrazol-magl-inhibitorer |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| CN117177744A (zh) | 2021-01-29 | 2023-12-05 | 塞迪拉治疗股份有限公司 | Cdk2抑制剂及其使用方法 |
| MX2023015436A (es) | 2021-06-26 | 2024-02-21 | Cedilla Therapeutics Inc | Inhibidores de cdk2 y metodos de uso de los mismos. |
| WO2023006893A1 (en) | 2021-07-30 | 2023-02-02 | Confo Therapeutics N.V. | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling |
| CA3234430A1 (en) * | 2021-11-02 | 2023-05-11 | Samuel George ANDREW | Crystalline forms of a monoacylglycerol lipase inhibitor |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017087854A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US20170247387A1 (en) * | 2014-07-25 | 2017-08-31 | Northeastern University | Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof |
| WO2018134698A1 (en) * | 2017-01-23 | 2018-07-26 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8455476B2 (en) * | 2009-04-22 | 2013-06-04 | Janssen Pharmaceutica, Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| US10093630B2 (en) * | 2014-05-21 | 2018-10-09 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2017087858A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| KR20170128029A (ko) * | 2016-05-13 | 2017-11-22 | 삼성에스디아이 주식회사 | 태양전지 전극 형성용 조성물 및 이로부터 제조된 전극 |
| DK3630744T3 (da) * | 2017-05-23 | 2023-03-06 | H Lundbeck As | Pyrazol-magl-inhibitorer |
| US10927105B1 (en) * | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
-
2019
- 2019-11-26 KR KR1020217019736A patent/KR20210097734A/ko not_active Ceased
- 2019-11-26 CA CA3120577A patent/CA3120577A1/en active Pending
- 2019-11-26 US US17/296,489 patent/US20220031676A1/en not_active Abandoned
- 2019-11-26 MX MX2021006312A patent/MX2021006312A/es unknown
- 2019-11-26 BR BR112020015043-6A patent/BR112020015043A2/pt unknown
- 2019-11-26 MA MA054313A patent/MA54313A/fr unknown
- 2019-11-26 SG SG11202105320YA patent/SG11202105320YA/en unknown
- 2019-11-26 WO PCT/US2019/063451 patent/WO2020112905A1/en not_active Ceased
- 2019-11-26 EP EP19889241.6A patent/EP3886844A4/en not_active Withdrawn
- 2019-11-26 JP JP2021529827A patent/JP2022509206A/ja active Pending
- 2019-11-26 AU AU2019389017A patent/AU2019389017B2/en not_active Expired - Fee Related
- 2019-11-26 CN CN201980090281.5A patent/CN113347971A/zh active Pending
-
2021
- 2021-05-25 CL CL2021001363A patent/CL2021001363A1/es unknown
- 2021-05-27 IL IL283508A patent/IL283508A/en unknown
- 2021-06-09 ZA ZA2021/03975A patent/ZA202103975B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170247387A1 (en) * | 2014-07-25 | 2017-08-31 | Northeastern University | Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof |
| WO2017087854A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2018134698A1 (en) * | 2017-01-23 | 2018-07-26 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202105320YA (en) | 2021-06-29 |
| CN113347971A (zh) | 2021-09-03 |
| US20220031676A1 (en) | 2022-02-03 |
| MA54313A (fr) | 2022-03-09 |
| AU2019389017A1 (en) | 2021-06-10 |
| IL283508A (en) | 2021-07-29 |
| WO2020112905A1 (en) | 2020-06-04 |
| CA3120577A1 (en) | 2020-06-04 |
| EP3886844A1 (en) | 2021-10-06 |
| CL2021001363A1 (es) | 2021-11-12 |
| MX2021006312A (es) | 2021-08-11 |
| KR20210097734A (ko) | 2021-08-09 |
| AU2019389017B2 (en) | 2025-01-09 |
| ZA202103975B (en) | 2023-11-29 |
| EP3886844A4 (en) | 2022-08-24 |
| BR112020015043A2 (pt) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022509206A (ja) | Ｍａｇｌ阻害剤による疾病の治療方法 | |
| US11634418B2 (en) | Amino acid compounds and methods of use | |
| JP6987859B2 (ja) | Ｍａｇｌ阻害剤 | |
| WO2017087858A1 (en) | Pyrazole compounds and methods of making and using same | |
| WO2019226991A1 (en) | Androgen receptor modulators and methods for their use | |
| TW201125585A (en) | Quaternary ammonium salt prodrugs | |
| JP2020504707A (ja) | Ｍａｇｌ阻害剤 | |
| JP2020500178A (ja) | Ｍａｇｌ阻害剤 | |
| RU2478621C2 (ru) | Производное циклогексана и его фармацевтическое применение | |
| WO2016105448A1 (en) | Imidazoline receptor type 1 ligands for use as therapeutics | |
| JP2010510325A (ja) | ７，８−飽和−４，５−エポキシ−モルフィナニウム類似体の（ｓ）−ｎ−立体異性体 | |
| JP7578602B2 (ja) | Ｐ２ｘ３修飾薬での治療 | |
| CA3213289A1 (en) | Phenalkylamines and methods of making and using the same | |
| JP6929857B2 (ja) | ６，７，８，９−テトラヒドロ−５Ｈ−ピリド［２，３−ｄ］アゼピンドーパミンＤ３リガンド | |
| JP2022523668A (ja) | Ｍａｇｌ阻害剤による疾病の治療方法 | |
| TWI784199B (zh) | Dp拮抗劑 | |
| US9463187B2 (en) | Methylphenidate derivatives and uses of them | |
| PT95735B (pt) | Processo para a preparacao de morfolinois e de composicoes farmaceuticas que os contem | |
| MX2007016217A (es) | Compuestos de alfa-(aril- o heteroaril-metil)-beta-piperidinopropa namida como antagonista del receptor orl1. | |
| JP3112356B2 (ja) | シクロペンテノン化合物及び該化合物を有効成分とする脳機能改善薬 | |
| WO2025155874A1 (en) | Methods and compounds for modulating immune response | |
| JP2013112657A (ja) | フェノキシメチルベンズアミド誘導体、その薬学的に許容される酸付加塩及びその医薬用途 | |
| BR122023003660B1 (pt) | Compostos inibidores duplos de magl e faah, composição farmacêutica e usos | |
| BR122022025791B1 (pt) | Compostos inibidores duplos de magl e faah, composição farmacêutica e usos | |
| BR122022025803B1 (pt) | Compostos inibidores duplos de magl e faah, composição farmacêutica e usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221117 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221117 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231214 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240312 |